

**Stanford University 2nd Annual Spinal Muscular Atrophy Continuing Medical Education Conference:
Best Practices for SMA in an Evolving Treatment Era: Advantages & Challenges of Multidisciplinary
Care**

**Department of Neurology, Neuromuscular Division
Stanford University School of Medicine
December 3-5, 2020**

Bibliography

Standard of Care:

- Finkel RS, Mercuri E, Meyer OH, et al. Diagnosis and management of spinal muscular atrophy: Part 2: Pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics. *Neuromuscul Disord.* 2018;28(3):197-207.
- Mercuri E, Finkel RS, Muntoni F, et al. Diagnosis and management of spinal muscular atrophy: Part 1: Recommendations for diagnosis, rehabilitation, orthopedic and nutritional care. *Neuromuscul Disord.* 2018;28(2):103-115.
- Wang CH, Finkel RS, Bertini ES, et al. Consensus statement for standard of care in spinal muscular atrophy. *J Child Neurol.* 2007;22(8):1027-1049.

Natural History of SMA:

- Chabanon A, Seferian AM, Daron A, et al. Prospective and longitudinal natural history study of patients with Type 2 and 3 spinal muscular atrophy: Baseline data NatHis-SMA study. *PLoS One.* 2018;13(7):e0201004.
- Coratti G, Pera MC, Lucibello S, et al. Age and baseline values predict 12 and 24-month functional changes in type 2 SMA. *Neuromuscul Disord.* 2020;10.1016/j.nmd.2020.07.005.
- Coratti G, Lucibello S, Pera MC, et al. Gain and loss of abilities in type II SMA: A 12-month natural history study. *Neuromuscul Disord.* 2020;10.1016/j.nmd.2020.07.004.
- Choi YA, Suh DI, Chae JH, Shin HI. Trajectory of change in the swallowing status in spinal muscular atrophy type I. *Int J Pediatr Otorhinolaryngol.* 2020;130:109818.
- De Sanctis R., Coratti G, Pasternak, A, et al. Developmental milestones in type I spinal muscular atrophy. *Neuromuscul Disord.* 2016;26(11), 754-759.
- De Sanctis R, Pane M, Coratti G, et al. Clinical phenotypes and trajectories of disease progression in type 1 spinal muscular atrophy. *Neuromuscul Disord.* 2018;28(1):24-28.
- Dunaway S, Montes J, McDermott MP, et al. Physical therapy services received by individuals with spinal muscular atrophy (SMA). *J Pediatr Rehabil Med.* 2016;9(1):35-44.

**Stanford University 2nd Annual Spinal Muscular Atrophy Continuing Medical Education Conference:
Best Practices for SMA in an Evolving Treatment Era: Advantages & Challenges of Multidisciplinary
Care**

**Department of Neurology, Neuromuscular Division
Stanford University School of Medicine
December 3-5, 2020**

- Dunaway S, Montes J, O'Hagen J, Sproule DM, Vivo DC, Kaufmann P. Independent mobility after early introduction of a power wheelchair in spinal muscular atrophy. *Journal of Child Neurology*. 2013;28:576-582.
- Dunaway S, Montes J, Ryan PA, Montgomery M, Sproule DM, De Vivo DC. Spinal muscular atrophy type III: trying to understand subtle functional change over time--a case report. *Journal of Child Neurology*. 2012;27:779-85.
- Eng GD, Binder H, Koch B. Spinal muscular atrophy: experience in diagnosis and rehabilitation management of 60 patients. *Archives of Physical Medicine and Rehabilitation*. 1984;65:549-53.
- Finkel RS, McDermott MP, Kaufmann P, et al. Observational study of spinal muscular atrophy type I and implications for clinical trials. *Neurology*. 2014;83:810-817.
- Finkel RS, Weiner DJ, Mayer OH, McDonough JM, Panitch HB. Respiratory muscle function in infants with spinal muscular atrophy type I. *Pediatr Pulmonol*. 2014;49(12):1234-1242.
- Kaufmann P, McDermott MP, Darras BT, et al. Observational study of spinal muscular atrophy type 2 and 3: functional outcomes over 1 year. *Archives of Neurology*. 2011;68:779-86.
- Kaufmann P, McDermott MP, Darras BT, et al. A Prospective cohort study of spinal muscular atrophy types 2 and 3. *Neurology*. 2012;79(18),1889-1897.
- Kolb SJ, Coffey CS, Yankey JW, et al. Natural history of infantile-onset spinal muscular atrophy. *Ann Neurol*. 2017;82(6):883-891.
- Kolb SJ, Coffey CS, Yankey JW, et al. Baseline results of the NeuroNEXT spinal muscular atrophy infant biomarker study. *Ann Clin Transl Neurol*. 2016;3(2):132-145.
- Kruitwagen-van Reenen ET, van der Pol L, Schroder C, et al. Social participation of adult patients with spinal muscular atrophy: Frequency, restrictions, satisfaction, and correlates. *Muscle Nerve*. 2018;58(6):805-811.
- Mazzone E, Bianco F, Main M, et al. Six minute walk test in type III spinal muscular atrophy: a 12 month longitudinal study. *Neuromuscul Disord*. 2013;23(8):624-628.
- Mercuri E, Finkel R, Montes J, et al. Patterns of disease progression in type 2 and 3 SMA: implications for clinical trials. *Neuromuscul Disord*. 2016;26(2): 126-131.

**Stanford University 2nd Annual Spinal Muscular Atrophy Continuing Medical Education Conference:
*Best Practices for SMA in an Evolving Treatment Era: Advantages & Challenges of Multidisciplinary
Care***

**Department of Neurology, Neuromuscular Division
Stanford University School of Medicine
December 3-5, 2020**

- Mercuri E, Lucibello S, Perulli M, et al. Longitudinal natural history of type I spinal muscular atrophy: a critical review. *Orphanet J Rare Dis.* 2020;15(1):84.
- Mercuri E, Lucibello S, Pera MC, et al. Long-term progression in type II spinal muscular atrophy: A retrospective observational study. *Neurology.* 2019;93(13):e1241-e1247.
- Montes J, McDermott MP, Mirek E, et al. Ambulatory function in spinal muscular atrophy: Age-related patterns of progression. *PLoS One.* 2018 Jun 26;13(6):e0199657. doi: 10.1371/journal.pone.0199657. eCollection 2018.
- Ou SF, Ho CS, Lee WT, et al. Natural history in spinal muscular atrophy Type I in Taiwanese population: A longitudinal study. *Brain Dev.* 2020;10.1016/j.braindev.2020.07.012.
- Pane M, Palermo C, Messina S, et al. An observational study of functional abilities in infants, children, and adults with type 1 SMA. *Neurology.* 2018;91(8):e696-e703.
- Sivo S, Mazzone E, Antonaci L, et al. Upper limb module in non-ambulant patients with spinal muscular atrophy: 12 month changes. *Neuromuscul Disord.* 2015; 25(3),212-215.
- van Bruggen HW, Wadman RI, Bronkhorst EM, et al. Mandibular dysfunction as a reflection of bulbar involvement in SMA type 2 and 3. *Neurology.* 2016;86(6):552-559.
- van der Heul AMB, Cuppen I, Wadman RI, et al. Feeding and Swallowing Problems in Infants with Spinal Muscular Atrophy Type 1: an Observational Study. *J Neuromuscul Dis.* 2020;7(3):323-330.
- Vazquez-Costa JF. Natural history data in adults with SMA. *Lancet Neurol.* 2020;19(7):564-565.
- Wadman RI, Wijngaarde CA, Stam M, et al. Muscle strength and motor function throughout life in a cross-sectional cohort of 180 patients with spinal muscular atrophy types 1c-4. *Eur J Neurol.* 2018;25(3):512-518.
- Wadman RI, Stam M, Gijzen M, et al. Association of motor milestones, SMN2 copy and outcome in spinal muscular atrophy types 0-4. *J Neurol Neurosurg Psychiatry.* 2017;88(4):365-367.

**Stanford University 2nd Annual Spinal Muscular Atrophy Continuing Medical Education Conference:
Best Practices for SMA in an Evolving Treatment Era: Advantages & Challenges of Multidisciplinary
Care**

**Department of Neurology, Neuromuscular Division
Stanford University School of Medicine
December 3-5, 2020**

- Wijngaarde CA, Stam M, de Kort FAS, Wadman RI, van der Pol WL. Limited maximal mouth opening in patients with spinal muscular atrophy complicates endotracheal intubation: An observational study. *Eur J Anaesthesiol.* 2018;35(8):629-631.
- Wijngaarde CA, Veldhoen ES, van Eijk RPA, et al. Natural history of lung function in spinal muscular atrophy. *Orphanet J Rare Dis.* 2020;15(1):88.
- Wijngaarde CA, Brink RC, de Kort FAS, et al. Natural course of scoliosis and lifetime risk of scoliosis surgery in spinal muscular atrophy. *Neurology.* 2019;93(2):e149-e158.
- Zerres K, Rudnik-Schoneborn S, Forrest E, Lusakowska A, Borkowska J, Hausmanowa-Petrusewicz I. A collaborative study on the natural history of childhood and juvenile onset proximal spinal muscular atrophy (type II and III SMA): 569 patients. *Journal of the Neurological Sciences.* 1997;146:67-72.

Outcome Measures:

- Alfano LN, Miller NF, Iammarino MA, et al. ACTIVE (Ability Captured Through Interactive Video Evaluation) workspace volume video game to quantify meaningful change in spinal muscular atrophy. *Dev Med Child Neurol.* 2020;62(3):303-309.
- Bartels B, Habets LE, Stam M, et al. Assessment of fatigability in patients with spinal muscular atrophy: development and content validity of a set of endurance tests. *BMC Neurol.* 2019;19(1):21.
- Bartels B, de Groot JF, Habets LE, et al. Fatigability in spinal muscular atrophy: validity and reliability of endurance shuttle tests. *Orphanet J Rare Dis.* 2020;15(1):75.
- Bertoli S, Foppiani A, De Amicis R, et al. Anthropometric measurement standardization for a multicenter nutrition survey in children with spinal muscular atrophy. *Eur J Clin Nutr.* 2019;10.1038/s41430-019-0392-2.
- Bishop KM, Montes J, Finkel RS. Motor milestone assessment of infants with spinal muscular atrophy using the hammersmith infant neurological Exam-Part 2: Experience from a nusinersen clinical study. *Muscle Nerve.* 2018;57(1):142-146.

**Stanford University 2nd Annual Spinal Muscular Atrophy Continuing Medical Education Conference:
Best Practices for SMA in an Evolving Treatment Era: Advantages & Challenges of Multidisciplinary
Care**

**Department of Neurology, Neuromuscular Division
Stanford University School of Medicine
December 3-5, 2020**

- Buonsenso D, Berti B, Palermo C, et al. Ultrasound assessment of diaphragmatic function in type 1 spinal muscular atrophy. *Pediatr Pulmonol.* 2020;55(7):1781-1788.
- Cano SJ, Mayhew A, Glanzman AM, et al. Rasch analysis of clinical outcome measures in spinal muscular atrophy. *Muscle Nerve.* 2014;49(3):422-430.
- Dunaway S, Montes J, Garber CE, et al. Performance of the timed "up & go" test in spinal muscular atrophy. *Muscle Nerve.* 2014;50(2):273-277.
- Dunaway Young S, Montes J, Kramer SS, et al. Six-minute walk test is reliable and valid in spinal muscular atrophy. *Muscle Nerve.* 2016;54(5):836-842.
- Elsheikh B, King W, Peng J, et al. Outcome measures in a cohort of ambulatory adults with spinal muscular atrophy. *Muscle Nerve.* 2020;61(2):187-191.
- Finkel, R., Bertini, E., Muntoni, F., & Mercuri, E. 209th ENMC International Workshop: Outcome measures and clinical trial readiness in Spinal Muscular Atrophy 7-9 November 2014, Heemskerk, The Netherlands. *Neuromuscul Disord.* 2015;25(7):593-602.
- Glanzman AM, Mazzone E, Main M, et al. The Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND): test development and reliability. *Neuromuscul Disord.* 2010;20(3):155-161.
- Glanzman AM, McDermott MP, Montes J, et al. Validation of the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND). *Pediatric physical therapy : the official publication of the Section on Pediatrics of the American Physical Therapy Association.* 2011;23(4):322-326.
- Glanzman AM, O'Hagen JM, McDermott MP, et al. Validation of the Expanded Hammersmith Functional Motor Scale in spinal muscular atrophy type II and III. *Journal of Child Neurology.* 2011;26(12):1499-1507.
- Gomez-Garcia de la Banda M, Amaddeo A, Khirani S, et al. Assessment of respiratory muscles and motor function in children with SMA treated by nusinersen. *Pediatr Pulmonol.* 2020;10.1002/ppul.25142.
- Goodwin AM, Cornett KMD, McKay MJ, et al. Limitations of 6-minute walk test reference values for spinal muscular atrophy. *Muscle Nerve.* 2020;61(3):375-382.

**Stanford University 2nd Annual Spinal Muscular Atrophy Continuing Medical Education Conference:
Best Practices for SMA in an Evolving Treatment Era: Advantages & Challenges of Multidisciplinary
Care**

**Department of Neurology, Neuromuscular Division
Stanford University School of Medicine
December 3-5, 2020**

- Iannaccone ST, Russman BS, Browne RH, Buncher CR, White M, Samaha FJ. Prospective analysis of strength in spinal muscular atrophy. DCN/Spinal Muscular Atrophy Group. *J Child Neurol.* 2000;15(2):97-101.
- Khirani S, Amaddeo A, Fauroux B. Cough, sniff and maximal static pressure patterns in spinal muscular atrophy. *Respir Physiol Neurobiol.* 2020;271:103308.
- Krosschell KJ, Maczulski JA, Scott C, et al. Reliability and validity of the TIMPSI for infants with spinal muscular atrophy type I. *Pediatr Phys Ther.* 2013 Summer;25(2):140-148; discussion 149.
- Krosschell KJ, Scott CB, Maczulski JA, et al. Reliability of the Modified Hammersmith Functional Motor Scale in young children with spinal muscular atrophy. *Muscle Nerve.* 2011;44(2):246-251.
- Krosschell KJ, Maczulski JA, Crawford TO, Scott C, Swoboda KJ. A modified Hammersmith functional motor scale for use in multi-center research on spinal muscular atrophy. *Neuromuscul Disord.* 2006;16(7):417-426.
- Main M, Kairon H, Mercuri E, Muntoni F. The Hammersmith functional motor scale for children with spinal muscular atrophy: a scale to test ability and monitor progress in children with limited ambulation. *Eur J Paediatr Neurol.* 2003;7(4):155-159.
- Mazzone E, Bianco F, Martinelli D, et al. Assessing upper limb function in nonambulant SMA patients: development of a new module. *Neuromuscul Disord.* 2011;21(6):406-412.
- Mazzone E, De Sanctis R, Fanelli L, et al. Hammersmith Functional Motor Scale and Motor Function Measure-20 in non ambulant SMA patients. *Neuromuscul Disord.* 2014;24(4):347-352.
- Mazzone E, Montes J, Main M, et al. Old measures and new scores in spinal muscular atrophy patients. *Muscle Nerve.* 2015;52(3):435-437.
- Mazzone ES, Mayhew A, Montes J, et al. Revised upper limb module for spinal muscular atrophy: Development of a new module. *Muscle Nerve.* 2017;55(6):869-874.
- Mercuri E, Messina S, Battini R, et al. Reliability of the Hammersmith functional motor scale for spinal muscular atrophy in a multicentric study. *Neuromuscul Disord.* 2006;16(2):93-98.

**Stanford University 2nd Annual Spinal Muscular Atrophy Continuing Medical Education Conference:
Best Practices for SMA in an Evolving Treatment Era: Advantages & Challenges of Multidisciplinary
Care**

**Department of Neurology, Neuromuscular Division
Stanford University School of Medicine
December 3-5, 2020**

- Mercuri E, Mazzone E, Montes J, Messina S, Schroth MK. Spinal muscular atrophy motor functional scales and measures of pulmonary function. In: Sumner CJ, Paushkin S, Ko C-P, eds. *Spinal Muscular Atrophy*: Academic Press; 2017:371-382.
- Messina S, Frongia AL, Antonaci L, et al. A critical review of patient and parent caregiver oriented tools to assess health-related quality of life, activity of daily living and caregiver burden in spinal muscular atrophy. *Neuromuscul Disord*. 2019;29(12):940-950.
- Montes J, Dunaway S, Garber CE, Chiriboga CA, De Vivo DC, Rao AK. Leg muscle function and fatigue during walking in spinal muscular atrophy type 3. *Muscle Nerve*. 2014;50(1):34-39.
- Montes J, Glanzman AM, Mazzone ES, et al. Spinal muscular atrophy functional composite score: A functional measure in spinal muscular atrophy. *Muscle Nerve*. 2015;52(6):942-947.
- Montes J, McDermott MP, Martens WB, et al. Six-Minute Walk Test demonstrates motor fatigue in spinal muscular atrophy. *Neurology*. 2010;74(10):833-838.
- Montes J, Young SD, Mazzone E, Main M, International Spinal Muscular Atrophy Consortium Clinical Evaluator Working G. *Neuromuscul Disord*. 2017;10.1016/j.nmd.2017.07.005.
- Montes J, Dunaway Young S, Mazzone ES, et al. Nusinersen improves walking distance and reduces fatigue in later-onset spinal muscular atrophy. *Muscle Nerve*. 2019;60(4):409-414.
- O'Hagen JM, Glanzman AM, McDermott MP, et al. An expanded version of the Hammersmith Functional Motor Scale for SMA II and III patients. *Neuromuscul Disord*. 2007;17(9-10):693-697.
- Pasternak A, Sideridis G, Fragala-Pinkham M, et al. Rasch analysis of the Pediatric Evaluation of Disability Inventory-computer adaptive test (PEDI-CAT) item bank for children and young adults with spinal muscular atrophy. *Muscle Nerve*. 2016;54(6):1097-1107.
- Pera MC, Coratti G, Forcina N, et al. Content validity and clinical meaningfulness of the HFMSE in spinal muscular atrophy. *BMC Neurol*. 2017;17(1):39.
- Pera MC, Coratti G, Mazzone ES, et al. Revised upper limb module for spinal muscular atrophy: 12 month changes. *Muscle Nerve*. 2019;59(4):426-430.
- Ramsey D, Scoto M, Mayhew A, et al. Revised Hammersmith Scale for spinal muscular atrophy: A SMA specific clinical outcome assessment tool. *PLoS One*. 2017;12(2):e0172346.

**Stanford University 2nd Annual Spinal Muscular Atrophy Continuing Medical Education Conference:
Best Practices for SMA in an Evolving Treatment Era: Advantages & Challenges of Multidisciplinary
Care**

**Department of Neurology, Neuromuscular Division
Stanford University School of Medicine
December 3-5, 2020**

- Ropars J, Barnerias C, Hully M, et al. Thoracic circumference: A new outcome measure in spinal muscular atrophy type 1? *Neuromuscul Disord*. 2019;29(6):415-421.
- Sansone VA, Walter MC, Attarian S, et al. Measuring Outcomes in Adults with Spinal Muscular Atrophy - Challenges and Future Directions - Meeting Report. *J Neuromuscul Dis*. 2020;10.3233/JND-200534.
- Stam M, Wadman RI, Bartels B, et al. A continuous repetitive task to detect fatigability in spinal muscular atrophy. *Orphanet J Rare Dis*. 2018;13(1):160.
- Stepien A, Jedrzejowska M, Guzek K, Rekowski W, Stepowska J. Reliability of four tests to assess body posture and the range of selected movements in individuals with spinal muscular atrophy. *BMC Musculoskelet Disord*. 2019;20(1):54.
- Stolte B, Bois JM, Bolz S, et al. Minimal clinically important differences in functional motor scores in adults with spinal muscular atrophy. *Eur J Neurol*. 2020;10.1111/ene.14472.
- Tiziano FD, Bertini E, Messina S, et al. Hammersmith functional score correlates with the SMN2 copy number: a multicentric study. *Neuromuscul Disord*. 2007;17(5):400-403.
- Trundell D, Le Scouiller S, Gorni K, Seabrook T, Vuillerot C, Group SMS. Validity and Reliability of the 32-Item Motor Function Measure in 2- to 5-Year-Olds with Neuromuscular Disorders and 2- to 25-Year-Olds with Spinal Muscular Atrophy. *Neurol Ther*. 2020;10.1007/s40120-020-00206-3.
- Vuillerot C, Payan C, Iwaz J, Ecochard R, Berard C, MFM Spinal Muscular Atrophy Study Group. Responsiveness of the motor function measure in patients with spinal muscular atrophy. *Arch Phys Med Rehabil*. 2013;94(8):1555–1561.
- Wijngaarde CA, Stam M, Otto LAM, et al. Muscle strength and motor function in adolescents and adults with spinal muscular atrophy. *Neurology*. 2020;10.1212/WNL.000000000010540

Clinical Trial Results and Real World Intervention Studies:

- Albrechtsen SS, Born AP, Boesen MS. Nusinersen treatment of spinal muscular atrophy - a systematic review. *Dan Med J*. 2020;67(9).

**Stanford University 2nd Annual Spinal Muscular Atrophy Continuing Medical Education Conference:
Best Practices for SMA in an Evolving Treatment Era: Advantages & Challenges of Multidisciplinary
Care**

**Department of Neurology, Neuromuscular Division
Stanford University School of Medicine
December 3-5, 2020**

- Al-Zaidy S, Pickard AS, Kotha K, et al. Health outcomes in spinal muscular atrophy type 1 following AVXS-101 gene replacement therapy. *Pediatr Pulmonol.* 2019;54(2):179-185.
- Al-Zaidy SA, Kolb SJ, Lowes L, et al. AVXS-101 (Onasemnogene Apeparvovec) for SMA1: Comparative Study with a Prospective Natural History Cohort. *J Neuromuscul Dis.* 2019;6(3):307-317.
- Audic F, de la Banda MGG, Bernoux D, et al. Effects of nusinersen after one year of treatment in 123 children with SMA type 1 or 2: a French real-life observational study. *Orphanet J Rare Dis.* 2020;15(1):148.
- Bertini E, Dessaud E, Mercuri E, et al. Safety and efficacy of olesoxime in patients with type 2 or non-ambulatory type 3 spinal muscular atrophy: a randomised, double-blind, placebo-controlled phase 2 trial. *Lancet Neurol.* 2017;16(7):513-522.
- Chen TH. Comment on: "Myostatin inhibition in combination with antisense oligonucleotide therapy improves outcomes in spinal muscular atrophy" by Zhou et al. *J Cachexia Sarcopenia Muscle.* 2020;10.1002/jcsm.12607.
- Chiriboga CA, Swoboda KJ, Darras BT, et al. Results from a phase 1 study of nusinersen (ISIS-SMN(Rx)) in children with spinal muscular atrophy. *Neurology.* 2016;86(10):890-897.
- Chiriboga CA, Marra J, LaMarca NM, et al. Lack of effect on ambulation of dalfampridine-ER (4-AP) treatment in adult SMA patients. *Neuromuscul Disord.* 2020;30(8):693-700.
- Dabbous O, Maru B, Jansen JP, et al. Survival, Motor Function, and Motor Milestones: Comparison of AVXS-101 Relative to Nusinersen for the Treatment of Infants with Spinal Muscular Atrophy Type 1. *Adv Ther.* 2019;36(5):1164-1176.
- Darras BT, Chiriboga CA, Iannaccone ST, et al. Nusinersen in later-onset spinal muscular atrophy: Long-term results from the phase 1/2 studies. *Neurology.* 2019;92(21):e2492-e2506.
- Darras BT, Farrar MA, Mercuri E, et al. An Integrated Safety Analysis of Infants and Children with Symptomatic Spinal Muscular Atrophy (SMA) Treated with Nusinersen in Seven Clinical Trials. *CNS Drugs.* 2019;33(9):919-932.

**Stanford University 2nd Annual Spinal Muscular Atrophy Continuing Medical Education Conference:
Best Practices for SMA in an Evolving Treatment Era: Advantages & Challenges of Multidisciplinary
Care**

**Department of Neurology, Neuromuscular Division
Stanford University School of Medicine
December 3-5, 2020**

- De Vivo DC, Bertini E, Swoboda KJ, et al. Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study. *Neuromuscul Disord.* 2019;29(11):842-856.
- Deymeer F. Nusinersen in SMA 2 and 3: Risks vs benefits. *Neurology.* 2020;95(4):151-152.
- Finkel RS, Chiriboga CA, Vajsar J, et al. Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study. *Lancet.* 2016;388(10063):3017-3026.
- Finkel RS, Mercuri E, Darras BT, et al. Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy. *N Engl J Med.* 2017;377(18):1723-1732.
- Frongia AL, Natera-de Benito D, Ortez C, et al. Salbutamol tolerability and efficacy in patients with spinal muscular atrophy type II. *Neuromuscul Disord.* 2019;29(7):517-524.
- Giovannetti AM, Pasanisi MB, Černiauskaitė M, Bussolino C, Leonardi M, Morandi L. Perceived efficacy of salbutamol by persons with spinal muscular atrophy: A mixed methods study. *Muscle Nerve.* 2016;54(5):843-849.
- Hagenacker T, Wurster CD, Gunther R, et al. Nusinersen in adults with 5q spinal muscular atrophy: a non-interventional, multicentre, observational cohort study. *Lancet Neurol.* 2020;19(4):317-325.
- Harada Y, Rao VK, Arya K, et al. Combination molecular therapies for type 1 spinal muscular atrophy. *Muscle Nerve.* 2020;10.1002/mus.27034.
- Jochmann E, Steinbach R, Jochmann T, et al. Experiences from treating seven adult 5q spinal muscular atrophy patients with Nusinersen. *Ther Adv Neurol Disord.* 2020;13:1756286420907803.
- Kissel JT, Elsheikh B, King WM, et al. SMA valiant trial: a prospective, double-blind, placebo-controlled trial of valproic acid in ambulatory adults with spinal muscular atrophy. *Muscle Nerve.* 2014;49(2):187-192.
- Kissel JT, Scott CB, Reyna SP, et al. SMA CARNIVAL TRIAL PART II: a prospective, single-armed trial of L-carnitine and valproic acid in ambulatory children with spinal muscular atrophy. *PLoS One.* 2011;6(7):e21296.

**Stanford University 2nd Annual Spinal Muscular Atrophy Continuing Medical Education Conference:
Best Practices for SMA in an Evolving Treatment Era: Advantages & Challenges of Multidisciplinary
Care**

**Department of Neurology, Neuromuscular Division
Stanford University School of Medicine
December 3-5, 2020**

- Krosschell KJ, Kissel JT, Townsend EL, et al. Clinical trial of L-Carnitine and valproic acid in spinal muscular atrophy type I. *Muscle Nerve*. 2018;57(2):193-199.
- Lee BH, Collins E, Lewis L, et al. Combination therapy with nusinersen and AVXS-101 in SMA type 1. *Neurology*. 2019;93(14):640-641.
- LoMauro A, Mastella C, Alberti K, Masson R, Aliverti A, Baranello G. Effect of Nusinersen on Respiratory Muscle Function in Different Subtypes of Type 1 Spinal Muscular Atrophy. *Am J Respir Crit Care Med*. 2019;10.1164/rccm.201906-1175LE.
- LoMauro A, Mastella C, Alberti K, et al. Reply to: Limited Assessment of Respiratory Muscle Response to Nusinersen Treatment in Infants with Spinal Muscular Atrophy. *Am J Respir Crit Care Med*. 2019;10.1164/rccm.201910-2022LE.
- Lowes LP, Alfano LN, Arnold WD, et al. Impact of Age and Motor Function in a Phase 1/2A Study of Infants With SMA Type 1 Receiving Single-Dose Gene Replacement Therapy. *Pediatr Neurol*. 2019;98:39-45.
- Matesanz SE, Curry C, Gross B, et al. Clinical Course in a Patient With Spinal Muscular Atrophy Type 0 Treated With Nusinersen and Onasemnogene Apeparvovec. *J Child Neurol*. 2020;35(11):717-723.
- Mendell JR, Al-Zaidy S, Shell R, et al. Single-dose gene-replacement therapy for spinal muscular atrophy. *N Engl J Med*. 2017;377(18):1713-1722.
- Mercuri E, Darras BT, Chiriboga CA, et al. Nusinersen versus sham control in later-onset spinal muscular atrophy. *N Engl J Med*. 2018;378(7):625-635.
- Mercuri E, Sansone V. Nusinersen in adults with spinal muscular atrophy: new challenges. *Lancet Neurol*. 2020;19(4):283-284.
- Miller RG, Moore DH, Dronsky V, et al. A placebo-controlled trial of gabapentin in spinal muscular atrophy. *J Neurol Sci*. 2001;191(1-2):127-131.
- Moshe-Lilie O, Visser A, Chahin N, Ragole T, Dimitrova D, Karam C. Nusinersen in adult patients with spinal muscular atrophy: Observations from a single center. *Neurology*. 2020;95(4):e413-e416.

**Stanford University 2nd Annual Spinal Muscular Atrophy Continuing Medical Education Conference:
Best Practices for SMA in an Evolving Treatment Era: Advantages & Challenges of Multidisciplinary
Care**

**Department of Neurology, Neuromuscular Division
Stanford University School of Medicine
December 3-5, 2020**

- Pane M, Coratti G, Sansone VA, et al. Nusinersen in type 1 spinal muscular atrophy: Twelve-month real-world data. *Ann Neurol.* 2019;86(3):443-451.
- Pechmann A, Baumann M, Bernert G, et al. Treatment with Nusinersen - Challenges Regarding the Indication for Children with SMA Type 1. *J Neuromuscul Dis.* 2020;7(1):41-46.
- Sansone VA, Albamonte E, Salmin F, et al. Intrathecal nusinersen treatment for SMA in a dedicated neuromuscular clinic: an example of multidisciplinary and integrated care. *Neurol Sci.* 2019;40(2):327-332.
- Sansone VA, Pirola A, Albamonte E, et al. Respiratory Needs in Patients with Type 1 Spinal Muscular Atrophy Treated with Nusinersen. *J Pediatr.* 2020;219:223-228 e224.
- Stam M, Wadman RI, Wijngaarde CA, et al. Protocol for a phase II, monocentre, double-blind, placebo-controlled, cross-over trial to assess efficacy of pyridostigmine in patients with spinal muscular atrophy types 2-4 (SPACE trial). *BMJ Open.* 2018;8(7):e019932.
- Sugimoto M, Aiba K, Koyama N, Yokochi K, Nishio H. Nusinersen helps restore walking ability in childhood spinal muscular atrophy. *Pediatr Int.* 2019;61(7):728-729.
- Swoboda KJ, Scott CB, Reyna SP, et al. Phase II open label study of valproic acid in spinal muscular atrophy. *PLoS One.* 2009;4(5):e5268.
- Swoboda KJ, Scott CB, Crawford TO, et al. SMA CARNI-VAL trial part I: double-blind, randomized, placebo-controlled trial of L-carnitine and valproic acid in spinal muscular atrophy. *PLoS One.* 2010;5(8):e12140.
- Szabo L, Gergely A, Jakus R, et al. Efficacy of nusinersen in type 1, 2 and 3 spinal muscular atrophy: Real world data from Hungarian patients. *Eur J Paediatr Neurol.* 2020;27:37-42.
- Waldrop MA, Karingada C, Storey MA, et al. Gene Therapy for Spinal Muscular Atrophy: Safety and Early Outcomes. *Pediatrics.* 2020;146(3).
- Walter MC, Drager B, Gunther R, et al. [Treatment evaluation in patients with 5q-associated spinal muscular atrophy : Real-world experience]. *Nervenarzt.* 2019;90(4):343-351.

**Stanford University 2nd Annual Spinal Muscular Atrophy Continuing Medical Education Conference:
Best Practices for SMA in an Evolving Treatment Era: Advantages & Challenges of Multidisciplinary
Care**

**Department of Neurology, Neuromuscular Division
Stanford University School of Medicine
December 3-5, 2020**

- Walter MC, Wenninger S, Thiele S, et al. Safety and Treatment Effects of Nusinersen in Longstanding Adult 5q-SMA Type 3 - A Prospective Observational Study. *J Neuromuscul Dis.* 2019;6(4):453-465.
- Wurster CD, Winter B, Wollinsky K, et al. Intrathecal administration of nusinersen in adolescent and adult SMA type 2 and 3 patients. *J Neurol.* 2019;266(1):183-194.
- Yeo CJJ, Simeone SD, Townsend EL, Zhang RZ, Swoboda KJ. Prospective Cohort Study of Nusinersen Treatment in Adults with Spinal Muscular Atrophy. *J Neuromuscul Dis.* 2020;7(3):257-268.
- Zhou H, Meng J, Malerba A, et al. Myostatin inhibition in combination with antisense oligonucleotide therapy improves outcomes in spinal muscular atrophy. *J Cachexia Sarcopenia Muscle.* 2020;11(3):768-782.

Newborn Screening:

- Baker M, Griggs R, Byrne B, et al. Maximizing the Benefit of Life-Saving Treatments for Pompe Disease, Spinal Muscular Atrophy, and Duchenne Muscular Dystrophy Through Newborn Screening: Essential Steps. *JAMA Neurol.* 2019;10.1001/jamaneurol.2019.1206.
- Bozorg Qomi S, Asghari A, Salmaninejad A, Mojarrad M. Spinal Muscular Atrophy and Common Therapeutic Advances. *Fetal Pediatr Pathol.* 2019;38(3):226-238.
- Brandsema JF, Gross BN, Matesanz SE. Diagnostic Testing for Patients with Spinal Muscular Atrophy. *Clin Lab Med.* 2020;40(3):357-367.
- Cavdarli B, Ozturk FN, Guntekin Ergun S, Ergun MA, Dogan O, Percin EF. Intelligent Ratio: A New Method for Carrier and Newborn Screening in Spinal Muscular Atrophy. *Genet Test Mol Biomarkers.* 2020;24(9):569-577.
- Dangouloff T, Burghes A, Tizzano EF, Servais L, Group NSS. 244th ENMC international workshop: Newborn screening in spinal muscular atrophy May 10-12, 2019, Hoofddorp, The Netherlands. *Neuromuscul Disord.* 2020;30(1):93-103.
- Glascock J, Sampson J, Haidet-Phillips A, et al. Treatment algorithm for infants diagnosed with spinal muscular atrophy through newborn screening. *J Neuromuscul Dis.* 2018;5(2):145-158.

**Stanford University 2nd Annual Spinal Muscular Atrophy Continuing Medical Education Conference:
Best Practices for SMA in an Evolving Treatment Era: Advantages & Challenges of Multidisciplinary
Care**

**Department of Neurology, Neuromuscular Division
Stanford University School of Medicine
December 3-5, 2020**

- Glascock J, Sampson J, Connolly AM, et al. Revised Recommendations for the Treatment of Infants Diagnosed with Spinal Muscular Atrophy Via Newborn Screening Who Have 4 Copies of SMN2. *J Neuromuscul Dis.* 2020;7(2):97-100.
- Gyngell C, Stark Z, Savulescu J. Drugs, genes and screens: The ethics of preventing and treating spinal muscular atrophy. *Bioethics.* 2020;34(5):493-501.
- Jalali A, Rothwell E, Botkin JR, Anderson RA, Butterfield RJ, Nelson RE. Cost-Effectiveness of Nusinersen and Universal Newborn Screening for Spinal Muscular Atrophy. *J Pediatr.* 2020;10.1016/j.jpeds.2020.07.033.
- Kariyawasam DST, Russell JS, Wiley V, Alexander IE, Farrar MA. The implementation of newborn screening for spinal muscular atrophy: the Australian experience. *Genet Med.* 2020;22(3):557-565.
- Kay DM, Stevens CF, Parker A, et al. Implementation of population-based newborn screening reveals low incidence of spinal muscular atrophy. *Genet Med.* 2020;22(8):1296-1302.
- Ke Q, Zhao ZY, Mendell JR, et al. Progress in treatment and newborn screening for Duchenne muscular dystrophy and spinal muscular atrophy. *World J Pediatr.* 2019;15(3):219-225.
- Kraszewski JN, Kay DM, Stevens CF, et al. Pilot study of population-based newborn screening for spinal muscular atrophy in New York state. *Genet Med.* 2018;20(6):608-613.
- Lopez-Chacon M, Buehner AN, Rao VK. Spinal Muscular Atrophy Diagnosed by Newborn Screening. *Pediatr Neurol Briefs.* 2019;33:5.
- Muller-Felber W, Vill K, Schwartz O, et al. Infants Diagnosed with Spinal Muscular Atrophy and 4 SMN2 Copies through Newborn Screening - Opportunity or Burden? *J Neuromuscul Dis.* 2020;7(2):109-117.
- Ross LF, Kwon JM. Spinal Muscular Atrophy: Past, Present, and Future. *Neoreviews.* 2019;20(8):e437-e451.
- Saffari A, Kolker S, Hoffmann GF, Weiler M, Ziegler A. Novel challenges in spinal muscular atrophy - How to screen and whom to treat? *Ann Clin Transl Neurol.* 2019;6(1):197-205.

**Stanford University 2nd Annual Spinal Muscular Atrophy Continuing Medical Education Conference:
Best Practices for SMA in an Evolving Treatment Era: Advantages & Challenges of Multidisciplinary
Care**

**Department of Neurology, Neuromuscular Division
Stanford University School of Medicine
December 3-5, 2020**

- Serra-Juhe C, Tizzano EF. Perspectives in genetic counseling for spinal muscular atrophy in the new therapeutic era: early pre-symptomatic intervention and test in minors. *Eur J Hum Genet.* 2019;27(12):1774-1782.

Rehabilitation (orthopedic, interventions, falls, fatigue, pain, etc.):

- Abeleira MT, Limeres J, Outumuro M, et al. Benefits of Maxillary Expansion for a Patient With Spinal Muscular Atrophy Type 2. *Am J Phys Med Rehabil.* 2019;98(4):e32-e34.
- Alves CRR. Exercise training: thinking ahead to counteract systemic manifestations of spinal muscular atrophy. *J Physiol.* 2019;597(24):5757-5758.
- Baranello G, Vai S, Broggi F, et al. Evolution of bone mineral density, bone metabolism and fragility fractures in Spinal Muscular Atrophy (SMA) types 2 and 3. *Neuromuscul Disord.* 2019;29(7):525-532.
- Bartels B, Montes J, van der Pol WL, de Groot JF. Physical exercise training for type 3 spinal muscular atrophy. *Cochrane Database Syst Rev.* 2019;3:CD012120.
- Bernatz JT, Anderson PA, Halanski MA. Cervical Kyphosis in Spinal Muscular Atrophy: A Case Report. *JBJS Case Connect.* 2020;10(2):e1900341.
- Binz C, Schreiber-Katz O, Kumpe M, et al. An observational cohort study on impact, dimensions and outcome of perceived fatigue in adult 5q-spinal muscular atrophy patients receiving nusinersen treatment. *J Neurol.* 2020;10.1007/s00415-020-10227
- Biondi O, Lopes P, Deseille C, et al. Physical exercise reduces cardiac defects in type 2 spinal muscular atrophy-like mice. *J Physiol.* 2012;590(22):5907-5925.
- Bora G, Subaşı-Yıldız Ş, Yeşbek-Kaymaz A, Bulut N, Alemdaroğlu İ, Tunca-Yılmaz Ö, et al. Effects of arm cycling exercise in spinal muscular atrophy type II patients: A pilot study. *J Child Neurol.* 2018;33(3):209-215.
- Bulut N, Yardimci BN, Ayvat E, Aran OT, Yılmaz O, Karaduman A. The effect of two different aerobic training modalities in a child with spinal muscular atrophy type II: a case report. *J Exerc Rehabil.* 2019;15(2):322-326.

**Stanford University 2nd Annual Spinal Muscular Atrophy Continuing Medical Education Conference:
Best Practices for SMA in an Evolving Treatment Era: Advantages & Challenges of Multidisciplinary
Care**

**Department of Neurology, Neuromuscular Division
Stanford University School of Medicine
December 3-5, 2020**

- Catteruccia C, Vaugier I, Leclair D, et al. Orthopedic management of scoliosis by Garches brace and spinal fusion in SMA type 2 children. *Journal of Neuromuscular Diseases*. 2015;2:463-470.
- Craig J, Hilderman C, Wilson G, Misovic R. Effectiveness of stretch interventions for children with neuromuscular disabilities: Evidence-based recommendations. *Pediatr Phys Ther*. 2016;28(3):262-275.
- Cunha MC, Oliveira AS, Labronici RH, Gabbai AA. Spinal muscular atrophy type II (intermediary) and III (Kugelberg-Welander). Evolution of 50 patients with physiotherapy and hydrotherapy in a swimming pool. *Arquivos de Neuro-Psiquiatria*. 1996;54:402-406.
- Davies NR, Galaretto E, Piantoni L, et al. Scoliosis in spinal muscular atrophy: is the preoperative magnetic resonance imaging necessary? *Spine Deform*. 2020;10.1007/s43390-020-00134-0.
- Di Pede C, Salamon E, Motta M, Agosto C, Benini F, Ferrari A. Spinal bracing and lung function in type-2 spinal muscular atrophy. *Eur J Phys Rehabil Med*. 2018.
- Dunaway Young S, Montes J, Kramer SS, Podwika B, Rao AK, De Vivo DC. Perceived fatigue in spinal muscular atrophy: A pilot study. *J Neuromuscul Dis*. 2019;6(1):109-117.
- Farber HJ, Phillips WA, Kocab KL, et al. Impact of scoliosis surgery on pulmonary function in patients with muscular dystrophies and spinal muscular atrophy. *Pediatr Pulmonol*. 2020;55(4):1037-1042.
- Fehlings DL, Kirsch S, McComas A, Chipman M, Campbell K. Evaluation of therapeutic electrical stimulation to improve muscle strength and function in children with types II/III spinal muscular atrophy. *Dev Med Child Neurol*. 2002;44:741-744.
- Frownfelter D, Stevens K, Massery M, Bernardoni G. Do abdominal cutouts in thoracolumbosacral orthoses increase pulmonary function? *Clin Orthop Relat Res*. 2014;472(2):720-726.
- Fujak A, Kopschina C, Forst R, Mueller LA, Forst J. Use of orthoses and orthopaedic technical devices in proximal spinal muscular atrophy. Results of survey in 194 SMA patients. *Disability and Rehabilitation Assistive Technology*. 2011;6:305-311.

**Stanford University 2nd Annual Spinal Muscular Atrophy Continuing Medical Education Conference:
Best Practices for SMA in an Evolving Treatment Era: Advantages & Challenges of Multidisciplinary
Care**

**Department of Neurology, Neuromuscular Division
Stanford University School of Medicine
December 3-5, 2020**

- Fujak A, Kopschina C, Gras F, Forst R, Forst J. Contractures of the upper extremities in spinal muscular atrophy type II. Descriptive clinical study with retrospective data collection. *Ortop Traumatol Rehabil.* 2010;12:410-419.
- Fujak A, Raab W, Schuh A, Richter S, Forst R, Forst J. Natural course of scoliosis in proximal spinal muscular atrophy type II and IIIa: descriptive clinical study with retrospective data collection of 126 patients. *BMC Musculoskelet Disord.* 2013;14:283.
- Fujak A, Kopschina C, Forst R, Gras F, Mueller LA, Forst J. Fractures in proximal spinal muscular atrophy. *Arch Orthop Trauma Surg.* 2010;130(6):775-780.
- Gobbo M, Lazzarini S, Vacchi L, et al. Exercise Combined with Electrotherapy Enhances Motor Function in an Adolescent with Spinal Muscular Atrophy Type III. *Case Rep Neurol Med.* 2019;2019:4839793.
- Granata C, Cornelio F, Bonfiglioli S, Mattutini P, Merlini L. Promotion of ambulation of patients with spinal muscular atrophy by early fitting of knee-ankle-foot orthoses. *Dev Med and Child Neurol.* 1987;29:221-224.
- Hartley S, Stockley R. It's more than just physical therapy: reported utilization of physiotherapy services for adults with neuromuscular disorders attending a specialist centre. *Disability and Rehabilitation.* 2013;35:282-290.
- Hell AK, Braunschweig L, Tsaknakis K, et al. Children With Spinal Muscular Atrophy With Prior Growth-Friendly Spinal Implants Have Better Results After Definite Spinal Fusion in Comparison to Untreated Patients. *Neurosurgery.* 2020;10.1093/neuros/nyaa053.
- Hensel N, Brickwedde H, Tsaknakis K, et al. Altered bone development with impaired cartilage formation precedes neuromuscular symptoms in Spinal Muscular Atrophy (SMA). *Hum Mol Genet.* 2020;10.1093/hmg/ddaa145.
- Jones MA, McEwen IR, Hansen L. Use of power mobility for a young child with spinal muscular atrophy. *Physical Therapy.* 2003;83:253-262.
- King W, Kissel JT, Montes J, De Vivo DC, Finkel RS. Six-minute walk test demonstrates motor fatigue in spinal muscular atrophy. *Neurology.* 2010;75(12):1121-1122; author reply 1122.

**Stanford University 2nd Annual Spinal Muscular Atrophy Continuing Medical Education Conference:
Best Practices for SMA in an Evolving Treatment Era: Advantages & Challenges of Multidisciplinary
Care**

**Department of Neurology, Neuromuscular Division
Stanford University School of Medicine
December 3-5, 2020**

- Kizina K, Stolte B, Totzeck A, et al. Fatigue in adults with spinal muscular atrophy under treatment with nusinersen. *Sci Rep.* 2020;10(1):11069.
- Kruse T, Lehmann HC, Braumann B, Fink GR, Wunderlich G. The Maximum Bite Force for Treatment Evaluation in Severely Affected Adult SMA Patients-Protocol for a Longitudinal Study. *Front Neurol.* 2020;11:139.
- Labianca L, Weinstein SL. Scoliosis and spinal muscular atrophy in the new world of medical therapy: providing lumbar access for intrathecal treatment in patients previously treated or undergoing spinal instrumentation and fusion. *J Pediatr Orthop B.* 2019;28(4):393-396.
- Lager C, Kroksmark AK. Pain in adolescents with spinal muscular atrophy and Duchenne and Becker muscular dystrophy. *European Journal of Paediatric Neurology.* 2015;19:537-546.
- Lemke D, Rothwell E, Newcomb TM, Swoboda KJ. Perceptions of equine-assisted activities and therapies by parents and children with spinal muscular atrophy. *Pediatric Physical Therapy.* 2014;26:237-244.
- Lewelt A, Krosschell KJ, Stoddard GJ, et al. Resistance strength training exercise in children with spinal muscular atrophy. *Muscle Nerve.* 2015;52:559-567.
- Lloyd Morris EH, Estilow T, Glanzman AM, Cusack SV, Yum SW. Improving Temporomandibular Range of Motion in People With Duchenne Muscular Dystrophy and Spinal Muscular Atrophy. *Am J Occup Ther.* 2020;74(2):7402205080p7402205081.
- Madsen KL, Hansen RS, Preisler N, Thogersen F, Berthelsen MP, Vissing J. Training improves oxidative capacity, but not function, in spinal muscular atrophy type III. *Muscle Nerve.* 2015;52:240-244.
- Matsumoto H, Mueller J, Konigsberg M, et al. Improvement of Pulmonary Function Measured by Patient-reported Outcomes in Patients With Spinal Muscular Atrophy After Growth-friendly Instrumentation. *J Pediatr Orthop.* 2020;10.1097/BPO.0000000000001656.
- McMillan HJ. Nusinersen: Evidence of sustained clinical improvement and lessened fatigue in older ambulatory patients with spinal muscular atrophy. *Muscle Nerve.* 2020;61(1):1-2.
- Montes J, Blumenschine M, Dunaway S, et al. Weakness and fatigue in diverse neuromuscular diseases. *Journal of Child Neurology.* 2013;28:1277-1283.

**Stanford University 2nd Annual Spinal Muscular Atrophy Continuing Medical Education Conference:
Best Practices for SMA in an Evolving Treatment Era: Advantages & Challenges of Multidisciplinary
Care**

**Department of Neurology, Neuromuscular Division
Stanford University School of Medicine
December 3-5, 2020**

- Montes J, Dunaway S, Garber CE, Chiriboga CA, De Vivo DC, Rao AK. Leg muscle function and fatigue during walking in spinal muscular atrophy type 3. *Muscle Nerve*. 2014;50:34-39.
- Montes J, Dunaway S, Montgomery MJ, et al. Fatigue leads to gait changes in spinal muscular atrophy. *Muscle Nerve*. 2011;43:485-488.
- Montes J, McDermott MP, Martens WB, et al. Six-minute walk test demonstrates motor fatigue in spinal muscular atrophy. *Neurology*. 2010;74:833-838.
- Montes J, Garber, CE, Kramer SS, et al. Single-blind, randomized, controlled clinical trial of exercise in ambulatory spinal muscular atrophy: Why are the results negative? *Journal of Neuromuscular Diseases*. 2015;2:463-470.
- Montes J, Yoon LH. Commentary on "Stander Use in Spinal Muscular Atrophy: Results From a Large Natural History Database". *Pediatr Phys Ther*. 2020;32(3):242.
- Montes J, McIsaac TL, Dunaway S, et al. Falls and spinal muscular atrophy: exploring cause and prevention. *Muscle Nerve*. 2013;47:118-123.
- Nasomyont N, Hornung LN, Wasserman H. Intravenous bisphosphonate therapy in children with spinal muscular atrophy. *Osteoporos Int*. 2020;31(5):995-1000.
- Ness K, Apkon SD. Bone health in children with neuromuscular disorders. *J Pediatr Rehabil Med*. 2014;7(2):133-142.
- Peeters LHC, Janssen M, Kingma I, van Dieen JH, de Groot IJM. Patients With Spinal Muscular Atrophy Use High Percentages of Trunk Muscle Capacity to Perform Seated Tasks. *Am J Phys Med Rehabil*. 2019;98(12):1110-1117.
- Rathore FA, Afridi A. Does physical exercise training improve functional performance in type 3 spinal muscular atrophy? A Cochrane Review summary with commentary. *Dev Med Child Neurol*. 2020;62(9):1014-1016.
- Salazar R, Montes J, Dunaway Young S, et al. Quantitative evaluation of lower extremity joint contractures in spinal muscular atrophy: Implications for motor function. *Pediatr Phys Ther*. 2018;30(3):209-215.

**Stanford University 2nd Annual Spinal Muscular Atrophy Continuing Medical Education Conference:
Best Practices for SMA in an Evolving Treatment Era: Advantages & Challenges of Multidisciplinary
Care**

**Department of Neurology, Neuromuscular Division
Stanford University School of Medicine
December 3-5, 2020**

- Salem Y, Gropack SJ. Aquatic therapy for a child with type III spinal muscular atrophy: a case report. *Physical & Occupational Therapy in Pediatrics*. 2010;30:313-324.
- Shen PC, Lu CC, Liang WC, et al. Predictors for Deformity Progression in a Spinal Muscular Atrophy Cohort After Scoliosis Correction Surgery. *Clin Spine Surg*. 2020;10.1097/BSD.0000000000000989.
- Skalsky AJ, McDonald CM. Prevention and management of limb contractures in neuromuscular diseases. *Am J Phys Med Rehabil Clin N Am*. 2012;23(3):675-687.
- Sproule DM, Montes J, Dunaway S, et al. Adiposity is increased among high-functioning, non-ambulatory patients with spinal muscular atrophy. *Neuromuscul Disord*. 2010;20(7):448-452.
- Stam M, Wadman RI, Bartels B, et al. A continuous repetitive task to detect fatigability in spinal muscular atrophy. *Orphanet J Rare Dis*. 2018;13(1):160.
- Stark C, Duran I, Cirak S, et al. Vibration-assisted home training program for children with spinal muscular atrophy. *Child Neurol Open*. 2018;5:2329048X18780477.
- Stepien A, Mazurkiewicz L, Maslanko K, Rekowski W, Jedrzejowska M. Cervical rotation, chest deformity and pelvic obliquity in patients with spinal muscular atrophy. *BMC Musculoskelet Disord*. 2020;21(1):726.
- Swarup I, MacAlpine EM, Mayer OH, et al. Impact of growth friendly interventions on spine and pulmonary outcomes of patients with spinal muscular atrophy. *Eur Spine J*. 2020;10.1007/s00586-020-06564-8.
- Tangsrud SE, Carlsen KC, Lund-Petersen I, Carlsen KH. Lung function measurements in young children with spinal muscle atrophy; a cross sectional survey on the effect of position and bracing. *Archives of Disease in Childhood*. 2001;84:521-524.
- Townsend EL, Simeone SD, Krosschell KJ, Zhang RZ, Swoboda KJ, Project Cure SMA Investigator Network. Stander Use in Spinal Muscular Atrophy: Results From a Large Natural History Database. *Pediatr Phys Ther*. 2020;32(3):235-241.
- Trabacca A, Lucarelli E, Pacifico R, Vespino T, Di Liddo A, Losito L. The International Classification of Functioning, Disability and Health-Children and Youth as a framework for the management of

**Stanford University 2nd Annual Spinal Muscular Atrophy Continuing Medical Education Conference:
Best Practices for SMA in an Evolving Treatment Era: Advantages & Challenges of Multidisciplinary
Care**

**Department of Neurology, Neuromuscular Division
Stanford University School of Medicine
December 3-5, 2020**

spinal muscular atrophy in the era of gene therapy: a proof-of-concept study. *Eur J Phys Rehabil Med.* 2020;56(2):243-251.

- Vai S, Bianchi ML, Moroni I, et al. Bone and spinal muscular atrophy. *Bone.* 2015;79:116-120.
- Vry J, Schubert IJ, Semler O, Haug V, Schonau E, Kirschner J. Whole-body vibration training in children with Duchenne muscular dystrophy and spinal muscular atrophy. *European Journal of Paediatric Neurology.* 2014;18:140-149.
- Lager C, Kroksmark AK. Pain in adolescents with spinal muscular atrophy and Duchenne and Becker muscular dystrophy. *European Journal of Paediatric Neurology.* 2015;19:537-546.

Quality of Life and Participation:

- Beernaert K, Lovgren M, Jeppesen J, et al. Parents' experiences of information and decision making in the care of their child with severe spinal muscular atrophy: A population survey. *J Child Neurol.* 2019;883073818822900.
- Belter L, Cruz R, Jarecki J. Quality of life data for individuals affected by spinal muscular atrophy: a baseline dataset from the Cure SMA Community Update Survey. *Orphanet J Rare Dis.* 2020;15(1):217.
- Benini F, Salamon E, Divisic A, Maghini I, Agosto C. Acknowledging Limits: Statistics and the Child's Quality of Life in Spinal Muscular Atrophy. *J Paediatr Child Health.* 2020;56(6):995-996.
- Chambers GM, Settumba SN, Carey KA, et al. Prenusinersen economic and health-related quality of life burden of spinal muscular atrophy. *Neurology.* 2020;95(1):e1-e10.
- Cremers CH, Fischer MJ, Kruitwagen-van Reenen ET, et al. Participation and mental well-being of mothers of home-living patients with spinal muscular atrophy. *Neuromuscul Disord.* 2019;29(4):321-329.
- Cruz R, Belter L, Wasnock M, Nazarelli A, Jarecki J. Evaluating Benefit-risk Decision-making in Spinal Muscular Atrophy: A First-ever Study to Assess Risk Tolerance in the SMA Patient Community. *Clin Ther.* 2019;41(5):943-960 e944.

**Stanford University 2nd Annual Spinal Muscular Atrophy Continuing Medical Education Conference:
Best Practices for SMA in an Evolving Treatment Era: Advantages & Challenges of Multidisciplinary
Care**

**Department of Neurology, Neuromuscular Division
Stanford University School of Medicine
December 3-5, 2020**

- Cruz R, Lenz M, Belter L, Hobby K, Jarecki J. The Voice of the Patient Report. Cure SMA 2018. <https://www.curesma.org/wp-content/uploads/2018/01/SMA-VoP-for-publication-1-22-2018.pdf>. Accessed 10.1.2020.
- Fischer MJ, Asselman FL, Kruitwagen-van Reenen ET, et al. Psychological well-being in adults with spinal muscular atrophy: the contribution of participation and psychological needs. *Disabil Rehabil.* 2020;42(16):2262-2270.
- Hjorth E, Kreicbergs U, Sejersen T, et al. Bereaved Parents More Satisfied With the Care Given to Their Child With Severe Spinal Muscular Atrophy Than Nonbereaved. *J Child Neurol.* 2019;34(2):104-112.
- Hoot NR. Nusinersen for Type 1 Spinal Muscular Atrophy: A Father's Perspective. *Pediatrics.* 2019;144(4).
- Hully M, Barnerias C, Chabaliere D, et al. Palliative Care in SMA Type 1: A Prospective Multicenter French Study Based on Parents' Reports. *Front Pediatr.* 2020;8:4.
- Gunther R, Wurster CD, Cordts I, et al. Patient-Reported Prevalence of Non-motor Symptoms Is Low in Adult Patients Suffering From 5q Spinal Muscular Atrophy. *Front Neurol.* 2019;10:1098.
- Hunter M, Heatwole C, Luebke E, Johnson NE. What matters most: A perspective from adult spinal muscular atrophy patients. *J Neuromuscul Dis.* 2016;3(3):425-429.
- Kiefer P, Kirschner J, Pechmann A, Langer T. Experiences of caregivers of children with spinal muscular atrophy participating in the expanded access program for nusinersen: a longitudinal qualitative study. *Orphanet J Rare Dis.* 2020;15(1):194.
- Kruitwagen-Van Reenen ET, Wadman RI, Visser-Meily JM, van den Berg LH, Schroder C, van der Pol WL. Correlates of health related quality of life in adult patients with spinal muscular atrophy. *Muscle Nerve.* 2016;54(5):850-855.
- Landfeldt E, Edström J, Sejersen T, Tulinius M, Lochmüller H, Kirschner J. Quality of life of patients with spinal muscular atrophy: A systematic review. *Eur J Paediatr Neurol.* 2019;10.1016/j.ejpn.2019.03.004.
- Lavie M, Niskorn H, Sagi L, Amirav I. Choosing Life with Spinal Muscular Atrophy Type 1. *Adv Ther.* 2020;37(5):1708-1713.

**Stanford University 2nd Annual Spinal Muscular Atrophy Continuing Medical Education Conference:
Best Practices for SMA in an Evolving Treatment Era: Advantages & Challenges of Multidisciplinary
Care**

**Department of Neurology, Neuromuscular Division
Stanford University School of Medicine
December 3-5, 2020**

- Lloyd AJ, Thompson R, Gallop K, Teynor M. Estimation Of The Quality Of Life Benefits Associated With Treatment For Spinal Muscular Atrophy. *Clinicoecon Outcomes Res.* 2019;11:615-622.
- McGraw S, Qian Y, Henne J, Jarecki J, Hobby K, Yeh WS. A qualitative study of perceptions of meaningful change in spinal muscular atrophy. *BMC Neurol.* 2017;17(1):68.
- Mercuri E, Messina S, Montes J, et al. Patient and parent oriented tools to assess health-related quality of life, activity of daily living and caregiver burden in SMA. Rome, 13 July 2019. *Neuromuscul Disord.* 2020;30(5):431-436.
- Mongiovi P, Dilek N, Garland C, et al. Patient reported impact of symptoms in spinal muscular atrophy (PRISM-SMA). *Neurology.* 2018;91(13):e1206-e1214.
- Osmanovic A, Ranxha G, Kumpe M, et al. Treatment expectations and patient-reported outcomes of nusinersen therapy in adult spinal muscular atrophy. *J Neurol.* 2020;267(8):2398-2407.
- Pacione M, Siskind CE, Day JW, Tabor HK. Perspectives on Spinraza (Nusinersen) treatment study: Views of individuals and parents of children diagnosed with spinal muscular atrophy. *J Neuromuscul Dis.* 2019;6(1):119-131.
- Pena-Longobardo LM, Aranda-Reneo I, Oliva-Moreno J, et al. The Economic Impact and Health-Related Quality of Life of Spinal Muscular Atrophy. An Analysis across Europe. *Int J Environ Res Public Health.* 2020;17(16).
- Qian Y, McGraw S, Henne J, Jarecki J, Hobby K, Yeh WS. Understanding the experiences and needs of individuals with Spinal Muscular Atrophy and their parents: a qualitative study. *BMC Neurol.* 2015;15(1):217.
- Vaidya S, Boes S. Measuring quality of life in children with spinal muscular atrophy: a systematic literature review. *Qual Life Res.* 2018;27(12):3087-3094.
- Wan HWY, Carey KA, D'Silva A, et al. Health, wellbeing and lived experiences of adults with SMA: a scoping systematic review. *Orphanet J Rare Dis.* 2020;15(1):70.

**Stanford University 2nd Annual Spinal Muscular Atrophy Continuing Medical Education Conference:
Best Practices for SMA in an Evolving Treatment Era: Advantages & Challenges of Multidisciplinary
Care**

**Department of Neurology, Neuromuscular Division
Stanford University School of Medicine
December 3-5, 2020**

- Wan HWY, Carey KA, D'Silva A, Kasparian NA, Farrar MA. "Getting ready for the adult world": how adults with spinal muscular atrophy perceive and experience healthcare, transition and well-being. *Orphanet J Rare Dis.* 2019;14(1):74.
- Weaver MS, Hanna R, Hetzel S, et al. A Prospective, Crossover Survey Study of Child- and Proxy-Reported Quality of Life According to Spinal Muscular Atrophy Type and Medical Interventions. *J Child Neurol.* 2020;35(5):322-330.

Perspectives:

- Arnold WD, Kassar D, Kissel JT. Spinal muscular atrophy: diagnosis and management in a new therapeutic era. *Muscle Nerve.* 2015;51(2):157-167.
- Burgart AM, Magnus D, Tabor HK et al. Ethical Challenges Confronted When Providing Nusinersen Treatment for Spinal Muscular Atrophy. *JAMA Pediatr.* 2018 Feb 1;172(2):188-192.
- Burgart AM, Collier J, Cho MK. Fairness and Transparency in an Expanded Access Program: Allocation of the Only Treatment for SMA1. *Am J Bioeth.* 2017 Oct;17(10):71-73.
- Chen TH. New and Developing Therapies in Spinal Muscular Atrophy: From Genotype to Phenotype to Treatment and Where Do We Stand? *International journal of molecular sciences.* 2020;21(9).
- Ciafaloni E, Russman BS. Nusinersen for spinal muscular atrophy: Not just for babies? *Neurology.* 2019;92(21):985-986.
- Dangouloff T, Servais L. Clinical Evidence Supporting Early Treatment Of Patients With Spinal Muscular Atrophy: Current Perspectives. *Ther Clin Risk Manag.* 2019;15:1153-1161.
- Darras BT, Mammas IN, Spandidos DA. Spinal muscular atrophy, pediatric virology and gene therapy: A challenge of modern weakness and hope. *Exp Ther Med.* 2018;15(4):3671-3672.
- D'Silva A, Farrar MA. Personalized medicine for children with spinal muscular atrophy: Toward the holy grail. *Muscle Nerve.* 2020;10.1002/mus.27030.
- d'Ydewalle C, Sumner CJ. Spinal muscular atrophy therapeutics: Where do we stand? *Neurotherapeutics.* 2015;12(2):303-316.

**Stanford University 2nd Annual Spinal Muscular Atrophy Continuing Medical Education Conference:
Best Practices for SMA in an Evolving Treatment Era: Advantages & Challenges of Multidisciplinary
Care**

**Department of Neurology, Neuromuscular Division
Stanford University School of Medicine
December 3-5, 2020**

- Farrar MA, Park SB, Vucic S, et al. Emerging therapies and challenges in spinal muscular atrophy. *Ann Neurol*. 2017;81(3):355-368.
- Farrar MA, Carey KA, Paguinto SG, Kasparian NA, De Abreu Lourenco R. "The Whole Game is Changing and You've Got Hope": Australian Perspectives on Treatment Decision Making in Spinal Muscular Atrophy. *Patient*. 2020;13(4):389-400.
- Gidaro T, Servais L. Nusinersen treatment of spinal muscular atrophy: current knowledge and existing gaps. *Dev Med Child Neurol*. 2019;61(1):19-24.
- Hensel N, Kubinski S, Claus P. The Need for SMN-Independent Treatments of Spinal Muscular Atrophy (SMA) to Complement SMN-Enhancing Drugs. *Front Neurol*. 2020;11:45.
- Howell K, Gibbs RM, Rubin LL. Spinal Muscular Atrophy: Huge Steps. *Cerebrum*. 2019 Mar 1;2019:cer-03-19. eCollection Mar-Apr 2019.
- Iyer AA, Barzilay JR, Tabor HK. Patient and family social media use surrounding a novel treatment for a rare genetic disease: a qualitative interview study. *Genet Med*. 2020 Nov;22(11):1830-1837.
- Jedrzejowska M, Kostera-Pruszczyk A. Spinal muscular atrophy - new therapies, new challenges. *Neurol Neurochir Pol*. 2020;54(1):8-13.
- Kariyawasam D, Carey KA, Jones KJ, Farrar MA. New and developing therapies in spinal muscular atrophy. *Paediatr Respir Rev*. 2018;28:3-10.
- Kolb SJ, Kissel JT. Spinal muscular atrophy. *Neurologic clinics*. 2015;33(4):831-846.
- Kolb SJ, Kissel JT. Spinal muscular atrophy: a timely review. *Arch Neurol*. 2011;68(8):979-984.
- Messina S, Sframeli M. New Treatments in Spinal Muscular Atrophy: Positive Results and New Challenges. *J Clin Med*. 2020;9(7).
- Meylemans A, De Bleecker J. Current evidence for treatment with nusinersen for spinal muscular atrophy: a systematic review. *Acta Neurol Belg*. 2019;119(4):523-533.

**Stanford University 2nd Annual Spinal Muscular Atrophy Continuing Medical Education Conference:
Best Practices for SMA in an Evolving Treatment Era: Advantages & Challenges of Multidisciplinary
Care**

**Department of Neurology, Neuromuscular Division
Stanford University School of Medicine
December 3-5, 2020**

- Pacak CA, Kang PB. The End of the Beginning: The Journey to Molecular Therapies for Spinal Muscular Atrophy. *Pediatr Neurol.* 2020;102:1-2.
- Pacione M, Siskind CE, Day JW, Tabor HK. Perspectives on Spinraza (Nusinersen) Treatment Study: Views of Individuals and Parents of Children Diagnosed with Spinal Muscular Atrophy. *J Neuromuscul Dis.* 2019;6(1):119-131.
- Pera MC, Coratti G, Berti B, et al. Diagnostic journey in Spinal Muscular Atrophy: Is it still an odyssey? *PLoS One.* 2020;15(3):e0230677.
- Ramdas S, Servais L. New treatments in spinal muscular atrophy: an overview of currently available data. *Expert Opin Pharmacother.* 2020;21(3):307-315.
- Schorling DC, Pechmann A, Kirschner J. Advances in Treatment of Spinal Muscular Atrophy - New Phenotypes, New Challenges, New Implications for Care. *J Neuromuscul Dis.* 2020;7(1):1-13.
- Smith M. Current and future treatments of spinal muscular atrophy. *Dev Med Child Neurol.* 2020;62(3):267.
- Sumner CJ, Crawford TO. Two breakthrough gene-targeted treatments for spinal muscular atrophy: challenges remain. *J Clin Invest.* 2018;128(8):3219-3227.
- Swoboda KJ, Kissel JT, Crawford TO, et al. Perspectives on clinical trials in spinal muscular atrophy. *J Child Neurol.* 2007;22(8):957-966.
- Tizzano EF, Finkel RS. Spinal muscular atrophy: A changing phenotype beyond the clinical trials. *Neuromuscul Disord.* 2017;27(10):883-889.
- Tizzano EF. Treating neonatal spinal muscular atrophy: A 21st century success story? *Early Hum Dev.* 2019;138:104851.
- Vu-Han TL, Weiss C, Pumberger M. Novel Therapies for Spinal Muscular Atrophy are Likely Changing the Patient Phenotype. *Spine J.* 2020;10.1016/j.spinee.2020.08.013.
- Williams L. Spinal Muscular Atrophy in the Age of Gene Therapy. *AACN Adv Crit Care.* 2020;31(1):86-91.

**Stanford University 2nd Annual Spinal Muscular Atrophy Continuing Medical Education Conference:
*Best Practices for SMA in an Evolving Treatment Era: Advantages & Challenges of Multidisciplinary
Care***

**Department of Neurology, Neuromuscular Division
Stanford University School of Medicine
December 3-5, 2020**

- Wirth B, Karakaya M, Kye MJ, Mendoza-Ferreira N. Twenty-Five Years of Spinal Muscular Atrophy Research: From Phenotype to Genotype to Therapy, and What Comes Next. *Annu Rev Genomics Hum Genet.* 2020;21:231-261.
- Waldrop MA, Elsheikh BH. Spinal Muscular Atrophy in the Treatment Era. *Neurologic clinics.* 2020;38(3):505-518.
- Yong J, Moffett M, Lucas S. Implementing a Global Expanded Access Program (EAP) for Infantile-Onset Spinal Muscular Atrophy (Type I): Understanding the Imperative, Impact and Challenges. *J Neuromuscul Dis.* 2019;6(2):227-231.